Welcome to our dedicated page for Reliance Global Group SEC filings (Ticker: EZRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reliance Global Group filings document material-event disclosures, governance matters, shareholder voting results, material agreements and capital-structure information for its insurance, InsurTech and strategic ventures activities. The company's 8-K reports cover Regulation FD disclosures, settlement agreements, compensation actions, securities references involving common stock and Series Warrants, and operating or financial-results updates.
The company's proxy and annual-meeting filings disclose board elections, auditor ratification, equity incentive plan matters and stockholder vote results. Filings also describe agreements related to LifeSci Global Group, the Innervate investment, promissory note arrangements and governance review of transactions involving the company's healthcare investment platform.
Reliance Global Group, Inc. approved and implemented a 1-for-40 reverse stock split of its common stock to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The amendment to the articles of incorporation is scheduled to become effective at 5:00 p.m. Eastern on May 15, 2026.
Every 40 existing shares will convert into one share, reducing the amount of common stock outstanding from approximately 22,230,563 shares to 555,764 shares, while authorized common shares will be set at 50 million and par value stays at $0.086 per share. Trading on a split-adjusted basis on the Nasdaq Capital Market under the symbol EZRA and new CUSIP 75946W504 is expected to begin on May 18, 2026, with each shareholder’s ownership percentage remaining the same.
Reliance Global Group (Nasdaq: EZRA) reported a first‑quarter 2026 net loss of $1.47 million, narrowing from $1.74 million a year earlier, as it continued reshaping its portfolio and cost structure. Commission revenue declined about 10% to $3.83 million, mainly due to selling several agencies in 2025, partly offset by roughly 11% organic growth in remaining businesses.
Operating expenses fell to $5.07 million from $5.64 million, but non‑GAAP AEBITDA turned to a loss of $0.43 million from a positive $0.15 million, largely because equity‑based compensation was much lower in 2026 and therefore added back less. Cash and restricted cash rose to $3.24 million with working capital of about $2.60 million and stockholders’ equity of $7.42 million.
The company invested about $0.50 million in Enquantum, taking a roughly 23.8% stake and recording an equity‑method loss of about $26,000. It also completed a public offering providing roughly $2.0 million in gross proceeds and realized about $0.84 million from warrant exercises, while modestly using its at‑the‑market program.
Subsequent to quarter‑end, Reliance formed majority‑owned LifeSci Global Group to invest about $2.0 million in Innervate Radiopharmaceuticals and expanded its equity line of credit to $50.0 million, with about $49.1 million remaining. The board approved a 1‑for‑40 reverse stock split to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement, highlighting listing risk alongside the company’s push into technology and life sciences through its EZRA International Group and Scale51 strategy.
Reliance Global Group, Inc. reported results from its 2026 Annual Meeting of Stockholders, held via live webcast. As of March 5, 2026, there were 21,253,013 common shares outstanding and entitled to vote, and 9,591,634 shares were represented, about 45.13% of those eligible.
Stockholders elected five directors to serve until the 2027 annual meeting and ratified Urish Popeck & Co., LLC as independent auditor for the year ending December 31, 2026. Each director nominee received over 3.27 million votes for, with substantial broker non-votes.
Investors also approved an amendment to the 2025 Equity Incentive Plan, increasing shares available for issuance by 14,000,000, from 2,000,000 to 16,000,000. In a separate proposal, stockholders approved issuing common shares in excess of the Nasdaq Exchange Cap under a Common Stock Purchase Agreement dated August 26, 2025, as amended.
Reliance Global Group formed LifeSci Global Group LLC, a majority-owned healthcare investment vehicle, and funded it using a Promissory Note of up to $2,000,000 from its subsidiary EZRA International Group.
LifeSci Global agreed to purchase up to 421,053 Innervate Radiopharmaceuticals units at $4.75 per unit, totaling about $2.0 million, with $500,000 funded at closing. The deal includes priority distributions and up to 210,526 warrants and was approved by independent directors as a related-party transaction, with committee reshuffling to ensure board independence.
Reliance Global Group, Inc. filed a post-effective prospectus supplement updating its registration to cover the securities issued in its January 29, 2026 public financing and the ongoing issuance of shares upon exercise of related warrants. The January 2026 Offering sold 7,219,259 shares, 188,149 pre-funded warrants, 14,814,816 common warrants and issued 518,519 placement agent warrants at a combined public offering price of $0.27 per unit (or $0.269 per pre-funded unit), generating gross proceeds of approximately $2.0 million. The prospectus registers up to 15,521,484 shares issuable upon exercise of the issued warrants, and summarizes exercise terms (common warrant exercise price $0.27, pre-funded warrant exercise price $0.001, placement agent warrant exercise price $0.3375) and related transfer, beneficial-ownership limitations and cashless-exercise provisions.
The filing also discloses recent corporate developments including the launch of EZRA International/Scale51, a staged equity investment in Enquantum (16% ownership to date, target 51% via milestone tranches), amendments expanding an equity line commitment to $50.0 million, repayment of approximately $5.0 million of long-term debt in 2025, adoption of a digital asset treasury strategy, and corporate governance updates (restated articles and amended bylaws). The company’s Nasdaq ticker changed to EZRA and the last reported sale price on April 28, 2026 was $0.1753 per share.
Reliance Global Group, Inc. (EZRA) updates its Form S-1 by converting the prospectus into a short-form post-effective amendment covering 7,219,259 shares of Common Stock, 188,149 Pre-Funded Warrants, 14,814,816 Common Warrants and 518,519 Placement Agent Warrants (and up to 15,521,484 shares issuable upon exercise).
The amendment reflects the closed January 29, 2026 public financing that generated approximately $2.0 million gross ($1.7 million net after fees), the Nasdaq ticker change to EZRA, launch of EZRA International and the Scale51 model, the Enquantum investment and amendments to the White Lion equity line extending capacity up to $50.0 million.
Reliance Global Group has launched RELI Exchange 2.0, the next phase of its InsurTech platform for independent insurance agencies, aimed at faster and more efficient growth. The company previously reported that health insurance policies written through RELI Exchange during the 2025 open enrollment period increased 72% year over year, while Personal Lines Property and Casualty written premium rose 36% year over year. Its broker network expanded from approximately 65 to about 300 agency partners since 2022. RELI Exchange 2.0 centralizes recruiting with defined pipeline stages, integrated task management and full communication tracking to support higher recruiting volumes without additional headcount and to lay groundwork for future automation and data-driven capabilities.
Reliance Global Group, Inc. Chairman and CEO Ezra Beyman reported an open-market purchase of 300,000 shares of Common Stock at a price of 0.1699 per share. Following this transaction, he directly holds 959,299.997 shares, with additional smaller indirect holdings through YES Americana Group, LLC and Reliance Global Holdings, LLC.
Reliance Global Group, Inc. filed an amendment to its annual report for the year ended December 31, 2025 to correct the list of exhibits. The company had inadvertently omitted its Compensation Recovery Policy dated November 13, 2023, which is now added as Exhibit 97.1.
The amendment also includes current-dated CEO and CFO certifications under Section 302 of the Sarbanes-Oxley Act but makes no changes to the financial statements or other disclosures in the original report. As of March 10, 2026, the company had 21,253,013 common shares outstanding, and non-affiliate common stock held a market value of about $5.3 million as of June 30, 2025.